A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model

NCT01241422 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: JNJ 40929837
DRUG: Placebo
DRUG: Montelukast

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.